• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Collegium Pharmaceutical, Inc. (COLL) Stock Price, News & Analysis

Collegium Pharmaceutical, Inc. (COLL) Stock Price, News & Analysis

Currency in USD Disclaimer

$29.95

-$0.46

(-1.51%)

Day's range
$29.8
Day's range
$30.76
50-day range
$28.97
Day's range
$42.29
  • Country: US
  • ISIN: US19459J1043
52 wk range
$25.16
Day's range
$42.29
  • CEO: Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.02
  • Piotroski Score 7.00
  • Grade Neutral
  • Symbol (COLL)
  • Company Collegium Pharmaceutical, Inc.
  • Price $29.95
  • Changes Percentage (-1.51%)
  • Change -$0.46
  • Day Low $29.80
  • Day High $30.76
  • Year High $42.29

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $38.50
  • High Stock Price Target $50.00
  • Low Stock Price Target $35.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.51
  • Trailing P/E Ratio 13.22
  • Forward P/E Ratio 13.22
  • P/E Growth 13.22
  • Net Income $48.16 M

Income Statement

Quarterly

Annual

Latest News of COLL

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Collegium Pharmaceutical, Inc. Frequently Asked Questions

  • What is the Collegium Pharmaceutical, Inc. stock price today?

    Today's price of Collegium Pharmaceutical, Inc. is $29.95 — it has decreased by -1.51% in the past 24 hours. Watch Collegium Pharmaceutical, Inc. stock price performance more closely on the chart.

  • Does Collegium Pharmaceutical, Inc. release reports?

    Yes, you can track Collegium Pharmaceutical, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Collegium Pharmaceutical, Inc. stock forecast?

    Watch the Collegium Pharmaceutical, Inc. chart and read a more detailed Collegium Pharmaceutical, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Collegium Pharmaceutical, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Collegium Pharmaceutical, Inc. stock ticker.

  • How to buy Collegium Pharmaceutical, Inc. stocks?

    Like other stocks, COLL shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Collegium Pharmaceutical, Inc.'s EBITDA?

    Collegium Pharmaceutical, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Collegium Pharmaceutical, Inc.’s financial statements.

  • What is the Collegium Pharmaceutical, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.0849643681, which equates to approximately 8.50%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Collegium Pharmaceutical, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Collegium Pharmaceutical, Inc.'s financials relevant news, and technical analysis. Collegium Pharmaceutical, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Collegium Pharmaceutical, Inc. stock currently indicates a “sell” signal. For more insights, review Collegium Pharmaceutical, Inc.’s technical analysis.

  • A revenue figure for Collegium Pharmaceutical, Inc. for its last quarter?

    Collegium Pharmaceutical, Inc. published it's last quarterly revenues at $159.30 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.